SCHEMBL5724068

SCHEMBL5724068

O=C1c2ccccc2C(=O)N1Cc1csc(N2CC(O)C2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 2/20 0.43
POLB P06746 3/20 0.41
MAPT P10636 2/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
HPGD P15428 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
AR P10275 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724251 0.83 PKM (0.40) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL5724422 0.82 DNM1L (0.33) DNM1L
SCHEMBL5724179 0.77 LMNA (0.38) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL5724279 0.73 HRH3 (0.43) MAPTDNM1L
SCHEMBL28685921 0.73 LMNA (0.62) LMNAALDH1A1MEN1KMT2APKM
SCHEMBL19762475 0.73 PKM (0.74) LMNAALDH1A1MEN1KMT2APKM
SCHEMBL3147864 0.73 ALDH1A1 (0.51) LMNAALDH1A1MEN1KMT2APKM
SCHEMBL12271588 0.73 ALDH1A1 (0.51) LMNAALDH1A1MEN1KMT2APKM
SCHEMBL5724065 0.72 KDM4E (0.55) LMNAALDH1A1POLBMAPTHPGD
Bromide SCHEMBL5897641 0.72 ALDH1A1 (0.50) LMNAALDH1A1MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1289498-C 1-methylcarbapenem derivatives SANKYO CO (JP) 2006-12-13 CN disclosed
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
CN-1486317-A 1-methylcarbapenem derivatives ������������ʽ���� 2004-03-31 CN disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD LMNA 3159/4885NPSR1 4794/4885ALDH1A1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.